logo-loader

Q BioMed extends clinical trial agreement with Washington University to study glaucoma drugs

Published: 12:05 26 Jul 2018 EDT

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin and Mannin Research CEO George Nikopoulos tell Proactive on Wednesday the two companies announced that it is extending its option agreement with Washington University in St Louis to allow for further analysis of GDF-15 as a biomarker for monitoring glaucoma.

Nikopoulos says the independent studies will provide insights into the role of GDF-15 that will aid future clinical studies.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 22 minutes ago